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Abstract
Angelman syndrome (AS) is a rare neurodevelopmental disorder that is characterised by severe global developmental
delays, ataxia, loss of speech, epilepsy, sleep disorders, and a happy disposition. There is currently no cure for AS,
though several pharmaceutical companies are anticipating drug trials for new therapies to treat AS. The Foundation
for Angelman Therapeutics (FAST) Australia therefore identified a need for a global AS patient registry to identify
patients for recruitment for clinical trials.
The Global AS Registry was deployed in September 2016 utilising the Rare Disease Registry Framework, an open-source
tool that enables the efficient creation and management of patient registries. The Global AS Registry is web-based and
allows parents and guardians worldwide to register, provide informed consent, and enter data on individuals with AS.
286 patients have registered in the first 8 months since deployment.
We demonstrate the successful deployment of the first patient-driven global registry for AS. The data generated from
the Global AS Registry will be crucial in identifying patients suitable for clinical trials and in informing research that will
identify treatments for AS, and ultimately improve the lives of individuals and their families living with AS.
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Background
Angelman syndrome (AS) is a rare neurodevelopmental
disorder caused by the loss of function of UBE3A, an
imprinted, maternally expressed gene on chromosome
15 [1, 2]. The syndrome was first described by Dr. Harry
Angelman in 1965 [3], and is characterised by severe
global developmental delays, ataxia, loss of speech, epi-
lepsy, sleep disorders, and a happy disposition [4–6].
The developmental delay of AS is generally noticed by
six to 12 months of age, with the clinical diagnosis
usually made between 1 and 4 years of age [7].
The estimated prevalence of AS is between 1:15,000–
24,000 [8, 9], and there is currently no cure. Individuals
with AS have a normal lifespan, and normally receive
medical therapy for seizures and physical, communication,
and behavioural therapies to help improve their quality
of life. Current research is investigating the molecular
mechanisms by which UBE3A deficiency results in AS,
and possible gene therapy treatments. With several
pharmaceutical companies anticipating drug trials for
new therapies to treat AS, the Foundation for Angelman
Therapeutics (FAST) Australia identified a need for a
global AS patient registry to further understand the
syndrome and to identify patients for recruitment for
clinical trials.
Patient registries are crucial tools used to collate in-
formation about rare diseases such as AS from affected
individuals around the world. Registries serve a number
of important purposes, including the identification of
individuals suitable for clinical trials and the collection
of data in a uniform manner that can inform research.
We have developed a Rare Disease Registry Framework
(RDRF) to enable the efficient deployment of web-
based registries [10–12].
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The RDRF is an open-source tool that empowers
registry administrators to construct web-based patient
registries with minimal software developer effort. The
RDRF incorporates a modular design with a graphical user
interface (GUI) that allows users to dynamically create all
data elements (DEs) that define a patient registry, which
can then be shared across registries. The RDRF takes a
conceptual approach to the design and development of
patient registries to ensure access, security, privacy, and
sustainability [10, 13–15], and has been used to deploy na-
tional and international registries [16–19].
We describe the deployment of the Global AS Registry
utilising the RDRF, through engagement and collabor-
ation with FAST Australia board members, researchers
and clinicians from Mater Research (Brisbane) and the
Royal Children’s Hospital (Melbourne), and researchers
and software developers from the Centre for Compara-
tive Genomics at Murdoch University. The Global AS
Registry is a worldwide initiative that will collect data on
individuals with AS through a series of online surveys in
order to build the largest and most comprehensive glo-
bal collection of information on AS to date. It is the first
online patient-driven registry for AS, with parents and
caregivers of individuals with AS driving the collection
of data.
The Global AS Registry will help medical professionals
and researchers to learn more about individuals with
AS, and will create new opportunities to gain insight
and understanding about AS. The Global AS Registry
will act as an important tool for both facilitating re-
search and enabling clinical trial sponsors to quickly
identify suitable patients for studies.
Registry governance
The Global AS Registry is governed by the Global AS
Registry Governance Board, and the Data Curator is re-
sponsible for the management of registry activities.
All requests for data are received by the Data Curator
and, depending on the type of requests, are reviewed by
the Governance Board (Fig. 1). The Global AS Registry
is patient-reported, with parents or guardians of individ-
uals with AS registering their details, providing informed
consent to participate in the registry, and completing a
series of online questionnaires organised into specific
Fig. 1 Functions of the Global Angelman Syndrome Registry. The formatting of this figure is adapted from Napier et al. [18]
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Modules. Due to the ability of the RDRF to assign per-
missions to multiple levels of users, parent and guard-
ian users can only view the patients they have added to
the registry, and only the Data Curator has administra-
tion privileges and access to data from all patients
defined in the registry. The Mater Health Services
Human Research Ethics Committee (HREC/13/MHS/
76), Mater Human Research Governance Committee
(RG-16-078-AM01) and Murdoch University Human
Research Ethics Committee (2016/216) reviewed and
approved this study.
Registry deployment, system architecture, and security
The Global AS Registry is web-based and accessed on-
line [20]. The registry was created using the RDRF, and
is hosted and maintained by the Centre for Comparative
Genomics at Murdoch University in Western Australia.
The RDRF is open-source, with the source code [21] and
the project page [22] available online.
The RDRF is built on top of Django 1.8 [23] utilising
PostgreSQL [24], HTML, CSS, YAML [25], Javascript,
jQeury [26] and Bootstrap [27]. The RDRF is typically
deployed via Docker containers [28] using uWSGI [29]
and nginx [30]. The Django secure package middleware
settings are enabled by default in the RDRF, including
secure socket layer (SSL) security (encrypts all web traffic
to and from the application), cross-site request forgery
(CSRF) checking, and login restrictions of all views.
Additionally, identifying demographic information is stored
separately to any clinical data (see Napier et al. [18]).
Patient registration, informed consent, and adding
patients
Parents and guardians of individuals with AS register
through an online registration page [31]. Select demo-
graphic details on the parent/guardian users and ‘patients’
(individuals with AS) are captured, with automatic ac-
count verification emails sent to each user upon registra-
tion. After the parent/guardian user has verified their
account, they are prompted to provide informed consent
through the Consent Module prior to clinical Modules
being made available to them (Fig. 1).
Upon logging into the registry, parent/guardian users
may easily add additional patients. All patients are linked
to a parent/guardian user, who provides informed con-
sent and completes each Module on their behalf.
Modules
Parent/guardian users are guided through a series of on-
line questionnaires organised into Modules, including:
Newborn and infancy history, History of diagnosis and
results, Illnesses or medical problems, Medical history,
Behaviour and development, Epilepsy, Medications
and interventions, Sleep, Sleep Disturbance Scale for
Children, and Pathology and diagnostics. Longitudinal
data collection will occur for selected modules approxi-
mately once a year. The RDRF enables the collection of
longitudinal data in a variety of contexts, through both
time-stamping of data entry in a data field and time
stamping of data according to an ‘assessment’ or ‘form’
date [16]. The baseline Minimum Data Set is described
in Tones et al. (Megan Tones, Meagan Cross, Chloe
Simons, Kathryn R Napier, Adam A Hunter, Matthew I
Bellgard, Helen Heussler: Research Protocol: The
Initiation, Design and Establishment of the Global
Angelman Syndrome Registry, submitted).
Results and discussion
The Global AS Registry was deployed in September 2016,
with 286 registrations received in the first 8 months since
deployment from 32 countries. Approximately half of all
patients have provided informed consent, with 35% of
patients commencing or completing clinical data entry
through the progression through the numerous Modules.
Initial statistics on reported key diagnostic measures are
described in Tones et al. (Megan Tones, Meagan Cross,
Chloe Simons, Kathryn R Napier, Adam A Hunter,
Matthew I Bellgard, Helen Heussler: Research Protocol:
The Initiation, Design and Establishment of the Global
Angelman Syndrome Registry, submitted).
The deployment of the Global AS Registry is the result
of extensive stakeholder engagement with researchers,
clinicians, patient advocacy groups, families, and soft-
ware developers, driven by FAST Australia. The contin-
ued success of the Global AS Registry will be due to the
passion of the Angelman Syndrome community to con-
tribute data to the registry, the continued promotion
and management of the registry through FAST Australia
and the Data Curator and Governance Committee, and
the flexibility and sustainability of the RDRF.
Through its modular design, the RDRF allows the Glo-
bal AS Registry to continue to evolve over time. For ex-
ample, new Modules and DEs are easily added to the
registry as required, and consent questions can be
amended, added or removed. Because the RDRF allows
the dynamic creation and management of all aspects of
registry creation (DEs, sections, Modules, consents, and
management of user permissions) by users with little or
no software development experience, the registry can be
easily managed and updated by the Data Curator. Due to
its open-source nature, future developments, enhance-
ments and feature requests are automatically included in
the registry, with the Global AS Registry benefiting from
design input from other registries (and vice versa).
Future enhancements to the Global AS Registry will
include features such as internationalisation, which
will expand the availability of the registry to non-
English speaking participants. Future improvements
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will link clinician log-in and view of their patients to the
optional consent to contact clinicians provided by parents/
guardians, which will enable the clinical verification of
patient-reported data. The RDRF also allows longitudinal
data to be easily captured and visualised, which may be in-
corporated into the Global AS Registry at a future date.
Conclusions
We have demonstrated the successful deployment of the
first patient-driven global registry for Angelman Syn-
drome utilising the RDRF. The Global AS Registry is web-
based, which allows parents and guardians of individuals
with AS from around the world to register and contribute
patient data to the registry in a secure manner. The data
generated from the Global AS Registry will be crucial in
identifying patients suitable for clinical trials and in
informing research that will identify treatments for AS,
and ultimately improve the lives of individuals and their
families living with AS.
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